|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Accounts receivable | |||||||||||||
| Inventories, net | |||||||||||||
| Prepaid expenses and other current assets | |||||||||||||
| Total current assets | |||||||||||||
| Property and equipment, net | |||||||||||||
| Intangible assets, net | |||||||||||||
| Investment in Chill N Out Chryotherapy – related party | |||||||||||||
| Total Other Assets | |||||||||||||
| Goodwill, provisional | |||||||||||||
| Other assets | |||||||||||||
| TOTAL ASSETS | |||||||||||||
| Accounts Payable and Accrued Expenses | |||||||||||||
| Current Portion Long-Term Debt | |||||||||||||
| Loans Payable – Related Party | |||||||||||||
| Accounts payable | |||||||||||||
| Accounts payable - related parties | |||||||||||||
| Accrued expenses | |||||||||||||
| Accrued interest - related party | |||||||||||||
| Notes payable and loans (including $522,500 in default) | |||||||||||||
| Notes payable and loans - related parties | |||||||||||||
| Deferred revenue | |||||||||||||
| Total current liabilities | |||||||||||||
| Long-Term Debt | |||||||||||||
| Royalty Liability | |||||||||||||
| Notes payable and loans, net of current | |||||||||||||
| TOTAL LIABILITIES | |||||||||||||
| Common stock, $0.001 par value; 1,500,000,000 shares authorized; 971,575,183 issued and outstanding as of March 31, 2026 and 969,017,081 as of December 31, 2025 | |||||||||||||
| Series A preferred stock, non-dividend, 2,500 votes per share, $0.001 par value, 50,000,000 authorized; issued and outstanding 3,800 shares | |||||||||||||
| Series A Preferred Stock | |||||||||||||
| Series B Preferred Stock | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Common Stock issuable, -0- as of December 31, 2025 and 1,936,000 as of December 31, 2024 | |||||||||||||
| Accumulated deficit | |||||||||||||
| Accumulated other comprehensive income | |||||||||||||
| TOTAL STOCKHOLDERS' DEFICIT | |||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT |
Loading...
